<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862650</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20258</org_study_id>
    <secondary_id>NCI-2021-02081</secondary_id>
    <nct_id>NCT04862650</nct_id>
  </id_info>
  <brief_title>Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcelo Bonomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel&#xD;
      and carboplatin in treating patients with squamous cell carcinoma of the head and neck that&#xD;
      has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy&#xD;
      with monoclonal antibodies, such as cemiplimab , may help the body's immune system attack the&#xD;
      cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy&#xD;
      drugs, like paclitaxel and carboplatin, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Giving cemiplimab in combination with paclitaxel and carboplatin may work better&#xD;
      in treating recurrent or metastatic squamous cell carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the overall response rate (ORR) at 12 weeks of treatment with the treatment&#xD;
      combination cemiplimab, paclitaxel, and carboplatin.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess toxicity/tolerance to the proposed treatment combination (a safety run-in phase&#xD;
      of ten patients will be performed initially).&#xD;
&#xD;
      II. To assess progression-free survival (PFS) and overall survival (OS) at one and two years.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Prospectively test the ability of our clinical nomogram to predict median OS in squamous&#xD;
      cell carcinoma of the head and neck (SCCHN) patients planning to receive first-line&#xD;
      cemiplimab in combination with low-dose weekly paclitaxel and carboplatin. II. To assess the&#xD;
      PFS and OS of patients with combined positive score (CPS) &lt;1%, &gt;1%, and &gt; 20%.&#xD;
&#xD;
      III. Compare the predictive power of our nomogram to that of CPS in the prospective cohort,&#xD;
      as well as evaluate the combined correlation of nomogram and CPS to median OS.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cemiplimab intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to&#xD;
      104 weeks, and paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes once weekly&#xD;
      (QW) for up to 24 weeks. Treatment continuous in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 14 days and then every 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>ORR defined as the proportion of patients with a documented complete response (CR) + partial response (PR) at week 12 of treatment based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. An ORR of 40% (percent) or higher will be consider a positive result. Simon two-stage optimal design will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the date of enrollment until documented disease progression, assessed up to 2 years</time_frame>
    <description>PFS will be calculated based on RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of patient enrollment into the trial until death, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Toxicity will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ability of our clinical nomogram to predict median OS in squamous cell carcinoma of the head and neck patients planning to receive first-line cemiplimab in combination with low-dose weekly paclitaxel and carboplatin</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>PFS of patients with combined positive score (CPS) &lt; 1%, &gt; 1%, and &gt; 20%</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>OS of patients with CPS &lt; 1%, &gt; 1%, and &gt; 20%</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Predictive power of our nomogram to that of CPS in the prospective cohort, as well as evaluate the combined correlation of nomogram and CPS to median OS</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Metastatic Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Metastatic Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Metastatic Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Metastatic Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Recurrent Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Recurrent Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Recurrent Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Recurrent Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of Unknown Primary</condition>
  <condition>Stage IV Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IV Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IV Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVA Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVA Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVA Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVB Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVB Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVB Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVC Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVC Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVC Lip and Oral Cavity Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (cemiplimab, paclitaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cemiplimab IV over 30 minutes every 3 weeks (Q3W) for up to 104 weeks, and paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes once weekly (QW) for up to 24 weeks. Treatment continuous in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cemiplimab, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cemiplimab, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Cemiplimab RWLC</other_name>
    <other_name>Cemiplimab-rwlc</other_name>
    <other_name>Libtayo</other_name>
    <other_name>REGN2810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cemiplimab, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent/metastatic (R/M) SCCHN of the oral cavity, oropharynx, larynx and&#xD;
             hypopharynx&#xD;
&#xD;
          -  No prior systemic therapy for treatment of R/M disease&#xD;
&#xD;
          -  Patients with squamous cell carcinoma of an unknown primary are eligible provided&#xD;
             their tumor tested positive for p-16 and they have previously received treatment for&#xD;
             locoregional head and neck cancer&#xD;
&#xD;
          -  Must be at least four weeks since prior systemic therapy, radiation and/or surgery&#xD;
&#xD;
          -  At least one measurable lesion as defined by Response Evaluation Criteria In Solid&#xD;
             Tumors (RECIST) v1.1 on screening computed tomography (CT) or magnetic resonance&#xD;
             imaging (MRI)&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  White blood cell (WBC) count &gt; 2,500 cells/uL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;1,500 cells/uL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 cells/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Creatinine =&lt; 1.6 mg/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.6 mg/dL&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]), serum&#xD;
             glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 2.5 x upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Potassium &gt;= lower limit of normal (LLN)&#xD;
&#xD;
          -  Willingness to use medically acceptable contraception throughout the study period and&#xD;
             four weeks after the final administration of treatment&#xD;
&#xD;
          -  For female subjects with reproductive potential: a negative serum pregnancy test at&#xD;
             baseline&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent and to comply with the&#xD;
             study visits and assessment schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease which is amenable to curative local therapy&#xD;
&#xD;
          -  Nasopharyngeal, salivary gland, lip, or sinonasal carcinoma&#xD;
&#xD;
          -  Disease that requires corticosteroids (&gt;10 mg prednisone or equivalent daily within&#xD;
             four weeks prior to the first dose of cemiplimab) or other immune suppressives at&#xD;
             baseline&#xD;
&#xD;
          -  Previous treatment with mAb-based immune therapies&#xD;
&#xD;
          -  Previous treatment with PI3K inhibitors&#xD;
&#xD;
          -  Known brain metastases, unless stable for at least 21 days prior to registration&#xD;
&#xD;
          -  Known infection human immunodeficiency virus (HIV), hepatitis B or C&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g., congestive heart failure, unstable or&#xD;
             uncontrolled angina, myocardial infarction) within the past six months&#xD;
&#xD;
          -  History of pneumonitis within the past five years&#xD;
&#xD;
          -  Recipient of live vaccines (including attenuated) within 30 days of study treatment&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Any other condition or circumstance that could interfere with adherence to the study's&#xD;
             procedures or requirements or otherwise compromise the study's objectives in the&#xD;
             opinion of the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo R Bonomi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo R. Bonomi, MD</last_name>
      <email>Marcelo.Bonomi@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Marcelo R. Bonomi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Marcelo Bonomi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

